Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6931094 | 0.89 | CACNA1B (0.44) | CACNA1B | |
| SCHEMBL4514305 | 0.88 | CACNA1B (0.53) | CACNA1BPDE1C | |
| SCHEMBL6931374 | 0.86 | CACNA1B (0.56) | CACNA1BPDE1CMAPTMEN1KMT2A | |
| SCHEMBL6932426 | 0.83 | CACNA1B (0.47) | CACNA1BPDE1C | |
| SCHEMBL6930275 | 0.82 | CACNA1B (0.51) | CACNA1BPDE1CMAPTMEN1KMT2A | |
| SCHEMBL6931087 | 0.81 | CACNA1B (0.53) | CACNA1BPDE1C | |
| SCHEMBL6925906 | 0.81 | CACNA1B (0.46) | CACNA1BALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4489450 | 0.79 | CACNA1B (0.55) | CACNA1B | |
| SCHEMBL7527493 | 0.78 | CACNA1B (0.65) | CACNA1B | |
| SCHEMBL6929233 | 0.77 | CACNA1B (0.49) | CACNA1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020193605-A1 | New dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193605-A1 | New dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885PDE1C 198/4885ALDH1A1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.